Cidara Therapeutics

Cidara entered a definitive agreement under which Merck will acquire the company for $221.50 per share, valuing the deal at about $9.2 billion and expected to close in Q1 2026. Shares rose as high as $218.85 and finished the day up 105%. The deal follows FDA fast track designation for Cidara’s CD388, a Phase 3 candidate to prevent influenza in higher-risk patients. » Więcej na finance.yahoo.com

Cidara Therapeutics entered a definitive agreement to be acquired by Merck for $9.2 billion, with Merck’s subsidiary offering $221.50 per share and the transaction expected to close in Q1 2026. The deal follows FDA fast track designation for Cidara’s influenza prevention candidate CD388, which is in a Phase 3 trial for high‑risk patients. Shares spiked to a near-decade high on the news, finishing the day up about 105%. » Więcej na finance.yahoo.com

Merck & Co. is reportedly in short-term talks to buy Cidara Therapeutics, a developer of a long-acting antibody drug to protect against influenza. Completion of the deal could value Cidara at around $3.3 billion in market capitalization including a premium. Amid the bidding battle, Cidara’s stock rose about 50% in after-hours trading. » Więcej na deraktionaer.de

Cidara Therapeutics reports significant progress in its product pipeline, advancing the phase‑III study of CD388 and expanding the patient population. The company has $476 million in liquidity and received a BARDA commitment of $339 million with up to $281 million in optional expansion. Production capacity is to be expanded through a partnership with WuXi AppTec. No revenue was recorded in the past quarter; the stock fell 1.1% in after‑hours trading. Cidara is targeting a BLA submission for 2027. » Więcej na de.investing.com

Baron Health Care Fund disclosed a new position in Cidara Therapeutics, citing a single‑dose long‑acting antiviral that showed up to 76% protection against symptomatic influenza over 24 weeks in a 5,000+ person Phase 2b trial with no safety issues. Cidara has begun a Phase 3 trial in older adults and high‑risk or immunocompromised patients and estimates an addressable U.S. population of over 100 million, with management forecasting attractive manufacturing economics. The stock has surged over the past year and Baron highlighted the drug’s potential as a universal, non‑vaccine preventative compared with current vaccine efficacy. » Więcej na finance.yahoo.com